The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens

MeSH terms

• Aged
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents / immunology*
• Antineoplastic Agents / therapeutic use*
• Female
• Humans
• Immunotherapy
• Male
• Prognosis
• Rituximab
• Societies, Medical
• Survival Rate
• Waldenstrom Macroglobulinemia / drug therapy*
• Waldenstrom Macroglobulinemia / immunology
• Waldenstrom Macroglobulinemia / pathology*